Zooms Q3 Beats On Revenue, Large Customer Wins Accelerate
| 17252MAP5 | 98.52 0.95 0.96% |
About 62% of 17252MAP5's investor base is looking to short. The analysis of the overall prospects from investing in CTAS 345 01 MAY 25 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 17252MAP5's historical and current headlines, can help investors time the market. In addition, many technical investors use CTAS 345 01 bond news signals to limit their universe of possible portfolio assets.
17252MAP5 |
Video conferencing platform Zoom reported Q3 CY2024 results beating Wall Streets revenue expectations, with sales up 3.6 percent year on year to 1.18 billion. The company expects next quarters revenue to be around 1.18 billion, close to analysts estimates. Its non-GAAP profit of 1.38 per share was 5.5 percent above analysts consensus estimates.
Read at finance.yahoo.com
 |
CTAS 345 01 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 17252MAP5 bond to make a market-neutral strategy. Peer analysis of 17252MAP5 could also be used in its relative valuation, which is a method of valuing 17252MAP5 by comparing valuation metrics with similar companies.
Peers
17252MAP5 Related Equities
| AKAN | Akanda Corp | 2.94 | ||||
| ALVO | Alvotech | 0.60 | ||||
| TFX | Teleflex Incorporated | 0.44 | ||||
| APAM | Artisan Partners | 0.33 | ||||
| CHBAY | Chiba Bank | 0.00 | ||||
| AVDL | Avadel Pharmaceuticals | 0.98 | ||||
| XTNT | Xtant Medical | 2.44 |
Other Information on Investing in 17252MAP5 Bond
17252MAP5 financial ratios help investors to determine whether 17252MAP5 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 17252MAP5 with respect to the benefits of owning 17252MAP5 security.